12:00 AM
Oct 03, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Esaxerenone: Phase III started

Daiichi began the double-blind, Japanese Phase III ESAX-HTN trial to compare 2.5 and 5 mg oral CS-3150 once daily after breakfast for 12 weeks vs. 50 mg oral eplerenone in about...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >